Disease · MONDO_0003193

bile duct adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bile duct adenocarcinoma. Diseases, record MONDO_0003193. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003193

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bile duct adenocarcinoma; Open Targets
Open Targets ID: MONDO_0003193; Open Targets
Disease Ontology: DOID:4896; Disease Ontology
NCI Thesaurus: C27813; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 4 of its 4 drugs, from ClinicalTrials.gov; Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CADONILIMAB	CHEMBL4594456	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DISITAMAB VEDOTIN	CHEMBL5095273	Antibody drug conjugate	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SURUFATINIB	CHEMBL4297190	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets60

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRM1	26S proteasome	1	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/11047	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	1	Receptor tyrosine-protein kinase erbB-2 binding agent	Phase 2	https://conductscience.org/library/genes/2064	Drugs and targets
FGFR1	Fibroblast growth factor receptor 1	1	Fibroblast growth factor receptor 1 inhibitor	Phase 2	https://conductscience.org/library/genes/2260	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
PDCD1	Programmed cell death protein 1	1	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PSMA1	26S proteasome	1	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5682	Drugs and targets
PSMA2	26S proteasome	1	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/5683	Drugs and targets

1 to 10 of 60

See all 60 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00085410	Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder	Phase 2	20	2017-06-14	Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer	BORTEZOMIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT06092645	Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma	Phase 2	48		Bile Duct Adenocarcinoma	CADONILIMAB, SURUFATINIB	Its record names the disease	ClinicalTrials.gov
NCT06383533	Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma	Phase 2	28		Bile Duct Adenocarcinoma Non-Resectable, HER2 Gene Mutation	CADONILIMAB, DISITAMAB VEDOTIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
24512954	RESULT	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003193

GET https://conductscience.org/api/diseases/v1/MONDO_0003193/targets?page=2

API reference For AI assistants